Reversible, competitive arginase inhibitor (IC50 = 2 μM). Exhibits 10-fold selectivity for human type II arginase over type I. Enhances the effect of acetylcholine on isolated aortic and mesenteric arterial rings. Inhibits growth of lung carcinoma implants in mice.

Custot et al (1997) The new α-amino acid Nω-hydroxy-nor-L-arginine: a high affinity inhibitor of arginase well adapted to bind to its manganese cluster. J.Am.Chem.Soc. 119 4086 |Colleluori and Ash et al (2001) Classical and slow-binding inhibitors of human type II arginase. Biochemistry 40 9356 PMID:11478904 |Huynh et al (2009) The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br.J.Pharmacol. 156 84 PMID:19133993 |Rodriguez et al (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64 5839 PMID:15313928